Peptidomics of Body Fluids

[1]  R. Arlinghaus,et al.  MECHANISM OF PEPTIDE BOND FORMATION IN POLYPEPTIDE SYNTHESIS. , 1964, Proceedings of the National Academy of Sciences of the United States of America.

[2]  D. Johnson,et al.  Isolation of albumin from whole human plasma and fractionation of albumin-depleted plasma. , 1976, The Biochemical journal.

[3]  P. Arnaud,et al.  A general method for fractionation of plasma proteins. Dye-ligand affinity chromatography on immobilized Cibacron blue F3-GA. , 1982, The Biochemical journal.

[4]  G. González-Ávila,et al.  Experimental diffuse interstitial renal fibrosis. A biochemical approach. , 1988, Laboratory investigation; a journal of technical methods and pathology.

[5]  W. Turski,et al.  Aminooxyacetic acid produces excitotoxic lesions in the rat striatum , 1991, Synapse.

[6]  Shah Pm.  Integrated maternal and child health and family planning. , 1991 .

[7]  J. Yates,et al.  An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database , 1994, Journal of the American Society for Mass Spectrometry.

[8]  A. Pollock,et al.  Matrix Metalloproteinase 2 (Gelatinase A) Regulates Glomerular Mesangial Cell Proliferation and Differentiation* , 1996, The Journal of Biological Chemistry.

[9]  S. Kamidono,et al.  Elevation of serum levels of matrix metalloproteinase‐2 and ‐3 as new predictors of recurrence in patients with urothelial carcinoma , 1996, Cancer.

[10]  J. Jorgenson,et al.  Ultrahigh-pressure reversed-phase liquid chromatography in packed capillary columns. , 1997, Analytical chemistry.

[11]  D. N. Perkins,et al.  Probability‐based protein identification by searching sequence databases using mass spectrometry data , 1999, Electrophoresis.

[12]  S. Gygi,et al.  Quantitative analysis of complex protein mixtures using isotope-coded affinity tags , 1999, Nature Biotechnology.

[13]  C. Craik,et al.  Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  F. McLafferty,et al.  Automated reduction and interpretation of , 2000, Journal of the American Society for Mass Spectrometry.

[15]  M. Schrader,et al.  Peptidomics technologies for human body fluids. , 2001, Trends in biotechnology.

[16]  S. Loening,et al.  Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. , 2001, Urology.

[17]  C.R. Jiménez,et al.  Searching Sequence Databases Over the Internet: Protein Identification Using MS‐Tag , 1998, Current protocols in protein science.

[18]  M. Schrader,et al.  Peptidomics: the comprehensive analysis of peptides in complex biological mixtures. , 2012, Combinatorial chemistry & high throughput screening.

[19]  J. Yates,et al.  An automated multidimensional protein identification technology for shotgun proteomics. , 2001, Analytical chemistry.

[20]  S. Loening,et al.  Correspondence re: C. F. M. Sier et al., Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin. Cancer Res., 6: 2333-2340, 2000. , 2001, Clinical Cancer Research.

[21]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[22]  J. Yates,et al.  Shotgun Proteomics and Biomarker Discovery , 2002, Disease markers.

[23]  T. Veenstra,et al.  Characterization of the Low Molecular Weight Human Serum Proteome*S , 2003, Molecular & Cellular Proteomics.

[24]  Zheng Yan,et al.  Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. , 2003, Urology.

[25]  Young Y. Wang,et al.  A simple affinity spin tube filter method for removing high‐abundant common proteins or enriching low‐abundant biomarkers for serum proteomic analysis , 2003, Proteomics.

[26]  R. Aebersold,et al.  Mass spectrometry-based proteomics , 2003, Nature.

[27]  M. Mann,et al.  Proteomic analysis of post-translational modifications , 2003, Nature Biotechnology.

[28]  H. D. de Bruijn,et al.  Sample preparation of human serum for the analysis of tumor markers. Comparison of different approaches for albumin and gamma-globulin depletion. , 2003, Journal of chromatography. A.

[29]  B. Incledon,et al.  Optimization of protein precipitation based upon effectiveness of protein removal and ionization effect in liquid chromatography-tandem mass spectrometry. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[30]  T. Veenstra,et al.  Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry , 2004, Proteomics.

[31]  S. Bryant,et al.  Open mass spectrometry search algorithm. , 2004, Journal of proteome research.

[32]  Robertson Craig,et al.  TANDEM: matching proteins with tandem mass spectra. , 2004, Bioinformatics.

[33]  G. Crooks,et al.  WebLogo: a sequence logo generator. , 2004, Genome research.

[34]  Rong-Fong Shen,et al.  Identification and proteomic profiling of exosomes in human urine. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Pirmohamed,et al.  A method for the rapid depletion of albumin and immunoglobulin from human plasma , 2004, Proteomics.

[36]  H. Tammen,et al.  Peptidomic analysis of human blood specimens: Comparison between plasma specimens and serum by differential peptide display , 2005, Proteomics.

[37]  D. Speicher,et al.  Depletion of multiple high‐abundance proteins improves protein profiling capacities of human serum and plasma , 2005, Proteomics.

[38]  Richard D. LeDuc,et al.  New and automated MSn approaches for top-down identification of modified proteins , 2005, Journal of the American Society for Mass Spectrometry.

[39]  Dekel Tsur,et al.  Identification of post-translational modifications by blind search of mass spectra , 2005, Nature Biotechnology.

[40]  W. Kolch,et al.  Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. , 2005, Mass spectrometry reviews.

[41]  B. Searle,et al.  Identification of protein modifications using MS/MS de novo sequencing and the OpenSea alignment algorithm. , 2005, Journal of proteome research.

[42]  P. Davidsson,et al.  Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples , 2005, Proteomics.

[43]  R. Beynon,et al.  Positional proteomics: selective recovery and analysis of N-terminal proteolytic peptides , 2005, Nature Methods.

[44]  W. Barrett,et al.  Differences among techniques for high‐abundant protein depletion , 2005, Proteomics.

[45]  I. Poola,et al.  Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis , 2005, Nature Medicine.

[46]  Mikhail M Savitski,et al.  New Data Base-independent, Sequence Tag-based Scoring of Peptide MS/MS Data Validates Mowse Scores, Recovers Below Threshold Data, Singles Out Modified Peptides, and Assesses the Quality of MS/MS Techniques* , 2005, Molecular & Cellular Proteomics.

[47]  Fang-Xiang Wu,et al.  Quality assessment of peptide tandem mass spectra , 2006, First International Multi-Symposiums on Computer and Computational Sciences (IMSCCS'06).

[48]  A. Olshen,et al.  Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.

[49]  E. Krause,et al.  Evaluation of the titanium dioxide approach for MS analysis of phosphopeptides. , 2006, Journal of mass spectrometry : JMS.

[50]  M. Mann,et al.  The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins , 2006, Genome Biology.

[51]  S. Loening,et al.  Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder , 2006, BMC urology.

[52]  A. Mazur,et al.  Plasma proteome analysis: 2D gels and chips. , 2006, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[53]  M. Fälth,et al.  SwePep, a Database Designed for Endogenous Peptides and Mass Spectrometry* , 2006, Molecular & Cellular Proteomics.

[54]  Ronald J. Moore,et al.  Evaluation of Multiprotein Immunoaffinity Subtraction for Plasma Proteomics and Candidate Biomarker Discovery Using Mass Spectrometry*S , 2006, Molecular & Cellular Proteomics.

[55]  R. Aebersold,et al.  Dynamic Spectrum Quality Assessment and Iterative Computational Analysis of Shotgun Proteomic Data , 2006, Molecular & Cellular Proteomics.

[56]  Alexander A. Zamyatnin,et al.  The EROP-Moscow oligopeptide database , 2005, Nucleic Acids Res..

[57]  Michael J MacCoss,et al.  Using BiblioSpec for Creating and Searching Tandem MS Peptide Libraries , 2007, Current protocols in bioinformatics.

[58]  O. Ryu,et al.  The discovery of biomarkers for type 2 diabetic nephropathy by serum proteome analysis , 2007, Proteomics. Clinical applications.

[59]  V. Thongboonkerd.  Recent progress in urinary proteomics , 2007, Proteomics. Clinical applications.

[60]  C. Overall,et al.  Identification of Candidate Angiogenic Inhibitors Processed by Matrix Metalloproteinase 2 (MMP-2) in Cell-Based Proteomic Screens: Disruption of Vascular Endothelial Growth Factor (VEGF)/Heparin Affin Regulatory Peptide (Pleiotrophin) and VEGF/Connective Tissue Growth Factor Angiogenic Inhibitory Co , 2007, Molecular and Cellular Biology.

[61]  Mi-Ryung Kim,et al.  Proteome analysis of serum from type 2 diabetics with nephropathy. , 2007, Journal of proteome research.

[62]  K. Evans,et al.  Endogenous peptides from biophysical and biochemical fractionation of serum analyzed by matrix-assisted laser desorption/ionization and electrospray ionization hybrid quadrupole time-of-flight. , 2007, Analytical biochemistry.

[63]  Ping Wang,et al.  Backbone cleavages and sequential loss of carbon monoxide and ammonia from protonated AGG: A combined tandem mass spectrometry, isotope labeling, and theoretical study , 2007, Journal of the American Society for Mass Spectrometry.

[64]  S. Diamond.  Methods for mapping protease specificity. , 2007, Current opinion in chemical biology.

[65]  Kai A. Reidegeld,et al.  Protein labeling by iTRAQ: A new tool for quantitative mass spectrometry in proteome research , 2007, Proteomics.

[66]  R. Caprioli,et al.  Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine. , 2007, Biochemical and biophysical research communications.

[67]  Alexey I Nesvizhskii,et al.  Analysis and validation of proteomic data generated by tandem mass spectrometry , 2007, Nature Methods.

[68]  J. Fowlkes,et al.  Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy , 2009, Endocrine.

[69]  Navdeep Jaitly,et al.  DeconMSn: a software tool for accurate parent ion monoisotopic mass determination for tandem mass spectra , 2008, Bioinform..

[70]  M. Mann,et al.  Integrated analysis of the cerebrospinal fluid peptidome and proteome. , 2008, Journal of proteome research.

[71]  Ruedi Aebersold,et al.  Building consensus spectral libraries for peptide identification in proteomics , 2008, Nature Methods.

[72]  F. Liu,et al.  The construction of a bioactive peptide database in Metazoa. , 2008, Journal of proteome research.

[73]  P. Andrews,et al.  A spectral clustering approach to MS/MS identification of post-translational modifications. , 2008, Journal of proteome research.

[74]  P. Righetti,et al.  The ProteoMiner in the proteomic arena: a non-depleting tool for discovering low-abundance species. , 2008, Journal of proteomics.

[75]  P. Pevzner,et al.  Spectral probabilities and generating functions of tandem mass spectra: a strike against decoy databases. , 2008, Journal of proteome research.

[76]  David T. Kaleta,et al.  Enhanced Detection of Low Abundance Human Plasma Proteins Using a Tandem IgY12-SuperMix Immunoaffinity Separation Strategy*S , 2008, Molecular & Cellular Proteomics.

[77]  H. Mischak,et al.  Discovery and validation of urinary biomarkers for prostate cancer , 2008, Proteomics. Clinical applications.

[78]  S. R. Gallant,et al.  Dye ligand chromatography. , 2008, Methods in molecular biology.

[79]  F. Ahmed.  The role of capillary electrophoresis-mass spectrometry to proteome analysis and biomarker discovery. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[80]  Ron Edgar,et al.  NCBI Peptidome: a new public repository for mass spectrometry peptide identifications , 2009, Nature Biotechnology.

[81]  C. Ronco,et al.  Today’s Approach to the Critically Ill Patient with Acute Kidney Injury , 2009, Blood Purification.

[82]  A. Salvador,et al.  Clinical Quantitation of Prostate-specific Antigen Biomarker in the Low Nanogram/Milliliter Range by Conventional Bore Liquid Chromatography-Tandem Mass Spectrometry (Multiple Reaction Monitoring) Coupling and Correlation with ELISA Tests , 2009, Molecular & Cellular Proteomics.

[83]  Sarah Boyd,et al.  PMAP: databases for analyzing proteolytic events and pathways , 2008, Nucleic Acids Res..

[84]  W. Van Criekinge,et al.  Spectral clustering in peptidomics studies helps to unravel modification profile of biologically active peptides and enhances peptide identification rate , 2009, Proteomics.

[85]  S. Yohannes,et al.  Evolving practices in the management of acute kidney injury in the ICU (Intensive Care Unit). , 2009, Clinical nephrology.

[86]  K. Gevaert,et al.  Improved visualization of protein consensus sequences by iceLogo , 2009, Nature Methods.

[87]  A. Vlahou,et al.  Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics , 2009, Clinical Cancer Research.

[88]  H. Mischak,et al.  Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. , 2009, Kidney international.

[89]  F. Reisinger,et al.  Database on Demand – An online tool for the custom generation of FASTA‐formatted sequence databases , 2009, Proteomics.

[90]  K. Schwamborn,et al.  Serum proteomic profiling in patients with bladder cancer. , 2009, European urology.

[91]  J. Kotzka,et al.  Combinatorial hexapeptide ligand libraries (ProteoMiner™): An innovative fractionation tool for differential quantitative clinical proteomics , 2009, Archives of physiology and biochemistry.

[92]  Gonzalo R. Ordóñez,et al.  The Degradome database: mammalian proteases and diseases of proteolysis , 2008, Nucleic Acids Res..

[93]  J. Wells,et al.  Methods for the proteomic identification of protease substrates. , 2009, Current opinion in chemical biology.

[94]  L. Foster,et al.  Cell-based identification of natural substrates and cleavage sites for extracellular proteases by SILAC proteomics. , 2009, Methods in molecular biology.

[95]  D. Duong,et al.  Systematical optimization of reverse-phase chromatography for shotgun proteomics. , 2009, Journal of proteome research.

[96]  P. Altevogt,et al.  ResearchADAM 10 is expressed in human podocytes and found in urinary vesicles of patients with glomerular kidney diseases , 2015 .

[97]  Rob Knight,et al.  A Simulated MS/MS Library for Spectrum-to-spectrum Searching in Large Scale Identification of Proteins*S , 2009, Molecular & Cellular Proteomics.

[98]  S. Hoving,et al.  Isoelectric focusing and two-dimensional gel electrophoresis. , 2009, Methods in enzymology.

[99]  Kevin C. Dorff,et al.  Urine proteomics for profiling of human disease using high accuracy mass spectrometry , 2009, Proteomics. Clinical applications.

[100]  A. Dominiczak,et al.  Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. , 2009, Mass spectrometry reviews.

[101]  V. Tesar,et al.  Fibroblast Growth Factor 23 and Matrix-Metalloproteinases in Patients with Chronic Kidney Disease: Are They Associated with Cardiovascular Disease? , 2009, Kidney and Blood Pressure Research.

[102]  T. Sui,et al.  Relationships between MMP-2, MMP-9, TIMP-1 and TIMP-2 levels and their pathogenesis in patients with lupus nephritis , 2010, Rheumatology International.

[103]  H. Mischak,et al.  Urinary proteomics based on capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application. , 2010, Advances in chronic kidney disease.

[104]  P. Pevzner,et al.  Deconvolution and Database Search of Complex Tandem Mass Spectra of Intact Proteins , 2010, Molecular & Cellular Proteomics.

[105]  Ruedi Aebersold,et al.  Options and considerations when selecting a quantitative proteomics strategy , 2010, Nature Biotechnology.

[106]  D. Celermajer,et al.  Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic dysfunction. , 2010, Diabetes research and clinical practice.

[107]  M. Girolami,et al.  Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease* , 2010, Molecular & Cellular Proteomics.

[108]  Lennart Martens,et al.  Peptide and protein quantification: A map of the minefield , 2010, Proteomics.

[109]  Kristin L Cheek,et al.  Depletion of abundant plasma proteins and limitations of plasma proteomics. , 2010, Journal of proteome research.

[110]  P. Højrup,et al.  Finding diabetic nephropathy biomarkers in the plasma peptidome by high‐throughput magnetic bead processing and MALDI‐TOF‐MS analysis , 2010, Proteomics. Clinical applications.

[111]  C. Overall,et al.  Multiplex N-terminome Analysis of MMP-2 and MMP-9 Substrate Degradomes by iTRAQ-TAILS Quantitative Proteomics* , 2010, Molecular & Cellular Proteomics.

[112]  Xifeng Wu,et al.  A multiplexed, particle‐based flow cytometric assay identified plasma matrix metalloproteinase‐7 to be associated with cancer‐related death among patients with bladder cancer , 2010, Cancer.

[113]  J. Bandow.  Comparison of protein enrichment strategies for proteome analysis of plasma , 2010, Proteomics.

[114]  A. Bankfalvi,et al.  Matrix metalloproteinase‐7 as a marker of metastasis and predictor of poor survival in bladder cancer , 2010, Cancer science.

[115]  M. Baker,et al.  High‐abundance protein depletion: Comparison of methods for human plasma biomarker discovery , 2010, Electrophoresis.

[116]  T. Tomonaga,et al.  High-yield peptide-extraction method for the discovery of subnanomolar biomarkers from small serum samples. , 2010, Journal of proteome research.

[117]  H. Parving,et al.  Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria , 2010, BMC nephrology.

[118]  H. Mischak,et al.  Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. , 2010, Kidney international.

[119]  C. Neusüss,et al.  Statistical evaluation of CZE‐UV and CZE‐ESI‐MS data of intact α‐1‐acid glycoprotein isoforms for their use as potential biomarkers in bladder cancer , 2010, Electrophoresis.

[120]  H. Bilo,et al.  Urinary matrix metalloproteinase-8 and -9 activities in type 2 diabetic subjects: A marker of incipient diabetic nephropathy? , 2010, Clinical biochemistry.

[121]  Sanjeeva Srivastava,et al.  Proteomic technologies for the identification of disease biomarkers in serum: Advances and challenges ahead , 2011, Proteomics.

[122]  Ronald J. Moore,et al.  Effectiveness of CID, HCD, and ETD with FT MS/MS for degradomic-peptidomic analysis: comparison of peptide identification methods. , 2011, Journal of proteome research.

[123]  Wen‐Cheng Chen,et al.  Urinary protein profiling by liquid chromatography/tandem mass spectrometry: ADAM28 is overexpressed in bladder transitional cell carcinoma. , 2011, Rapid communications in mass spectrometry : RCM.

[124]  Inez Finoulst,et al.  Sample Preparation Techniques for the Untargeted LC-MS-Based Discovery of Peptides in Complex Biological Matrices , 2011, Journal of biomedicine & biotechnology.

[125]  P. Zürbig,et al.  Human urinary peptide database for multiple disease biomarker discovery , 2011, Proteomics. Clinical applications.

[126]  Yusuke Nakamura,et al.  A Comprehensive Peptidome Profiling Technology for the Identification of Early Detection Biomarkers for Lung Adenocarcinoma , 2011, PloS one.

[127]  Chen Shao,et al.  A Tool for Biomarker Discovery in the Urinary Proteome: A Manually Curated Human and Animal Urine Protein Biomarker Database* , 2011, Molecular & Cellular Proteomics.

[128]  N. Boyd,et al.  Mammographic density and breast cancer risk: current understanding and future prospects , 2011, Breast Cancer Research.

[129]  C. Overall,et al.  TopFIND, a knowledgebase linking protein termini with function , 2011, Nature Methods.

[130]  Knut Reinert,et al.  Tools for Label-free Peptide Quantification , 2012, Molecular & Cellular Proteomics.

[131]  C. Ruan,et al.  Von Willebrand factor, ADAMTS13 activity, TNF-α and their relationships in patients with chronic kidney disease. , 2011, Experimental and therapeutic medicine.

[132]  E. Schiffer,et al.  Urinary proteome analysis for prostate cancer diagnosis: Cost‐effective application in routine clinical practice in Germany , 2012, International journal of urology : official journal of the Japanese Urological Association.

[133]  Phillip C. Wright,et al.  An insight into iTRAQ: where do we stand now? , 2012, Analytical and Bioanalytical Chemistry.

[134]  A. Caseiro,et al.  Protease profiling of different biofluids in type 1 diabetes mellitus. , 2012, Clinical biochemistry.

[135]  Richard D. Smith,et al.  IgY14 and SuperMix immunoaffinity separations coupled with liquid chromatography-mass spectrometry for human plasma proteomics biomarker discovery. , 2012, Methods.

[136]  A. Vlahou,et al.  A comparison between MALDI-MS and CE-MS data for biomarker assessment in chronic kidney diseases. , 2012, Journal of proteomics.

[137]  R. MacIsaac,et al.  Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy , 2012, Diabetes.

[138]  Richard D. Smith,et al.  Improving collision induced dissociation (CID), high energy collision dissociation (HCD), and electron transfer dissociation (ETD) fourier transform MS/MS degradome-peptidome identifications using high accuracy mass information. , 2012, Journal of proteome research.

[139]  Kelly A. Jones,et al.  Assessment of two immunodepletion methods: off-target effects and variations in immunodepletion efficiency may confound plasma proteomics. , 2012, Journal of proteome research.

[140]  H. Mischak,et al.  A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus , 2013, Diabetologia.

[141]  L. Tomlinson,et al.  Elastin Degradation Is Associated With Progressive Aortic Stiffening and All-Cause Mortality in Predialysis Chronic Kidney Disease , 2012, Hypertension.

[142]  A. Vlahou,et al.  Evaluation of the Zucker Diabetic Fatty (ZDF) Rat as a Model for Human Disease Based on Urinary Peptidomic Profiles , 2012, PloS one.

[143]  A. Vlahou,et al.  Improving peptide relative quantification in MALDI‐TOF MS for biomarker assessment , 2013, Proteomics.

[144]  D. Tarng,et al.  Progression of Kidney Disease in Non-Diabetic Patients with Coronary Artery Disease: Predictive Role of Circulating Matrix Metalloproteinase-2, -3, and -9 , 2013, PloS one.

[145]  J. Larkin,et al.  Current and future systemic treatments for renal cell carcinoma. , 2013, Seminars in cancer biology.

[146]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[147]  A. Vlahou,et al.  IMAC fractionation in combination with LC-MS reveals H2B and NIF-1 peptides as potential bladder cancer biomarkers. , 2013, Journal of proteome research.

[148]  V. Tesar,et al.  Changes in levels of matrix metalloproteinase-2 and -9, pregnancy-associated plasma protein-A in patients with various nephropathies. , 2013, Journal of nephrology.

[149]  O. Jensen,et al.  Depletion of abundant plasma proteins by poly(N-isopropylacrylamide-acrylic acid) hydrogel particles. , 2014, Analytical chemistry.

[150]  Aditi Chatterjee,et al.  Plasma Proteome Database as a resource for proteomics research: 2014 update , 2013, Nucleic Acids Res..

[151]  A. Vlahou,et al.  Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. , 2014, Journal of proteomics.

[152]  Henry Lam,et al.  Hunting for unexpected post-translational modifications by spectral library searching with tier-wise scoring. , 2014, Journal of proteome research.

[153]  A. Vlahou,et al.  Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases , 2014, Expert review of proteomics.

[154]  J. Jankowski,et al.  Absolute quantification of endogenous angiotensin II levels in human plasma using ESI-LC-MS/MS , 2014, Clinical Proteomics.

[155]  D. Formanowicz,et al.  Deeper insight into chronic kidney disease-related atherosclerosis: comparative proteomic studies of blood plasma using 2DE and mass spectrometry , 2015, Journal of Translational Medicine.

[156]  H. Mischak,et al.  Comparison of CE‐MS/MS and LC‐MS/MS sequencing demonstrates significant complementarity in natural peptide identification in human urine , 2014, Electrophoresis.

[157]  Z. Werb,et al.  Remodelling the extracellular matrix in development and disease , 2014, Nature Reviews Molecular Cell Biology.

[158]  A. Vlahou,et al.  Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. , 2015, Journal of the American Society of Nephrology : JASN.

[159]  A. Vlahou,et al.  New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[160]  G. Heinze,et al.  Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes , 2015, Journal of hypertension.

[161]  A. Vlahou,et al.  Capillary zone electrophoresis on‐line coupled to mass spectrometry: A perspective application for clinical proteomics , 2015, Proteomics. Clinical applications.

[162]  H. Mischak.  Pro: urine proteomics as a liquid kidney biopsy: no more kidney punctures! , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[163]  N. Bache,et al.  Targeted mass spectrometry analysis of the proteins IGF1, IGF2, IBP2, IBP3 and A2GL by blood protein precipitation. , 2015, Journal of proteomics.

[164]  A. Vlahou,et al.  CE‐MS‐based proteomics in biomarker discovery and clinical application , 2015, Proteomics. Clinical applications.

[165]  A. Vlahou,et al.  Developing proteomic biomarkers for bladder cancer: towards clinical application , 2015, Nature Reviews Urology.

[166]  Jian Wang,et al.  NeuroPep: a comprehensive resource of neuropeptides , 2015, Database J. Biol. Databases Curation.

[167]  G. Heinze,et al.  Identification of the Vasoconstriction-Inhibiting Factor (VIF), a Potent Endogenous Cofactor of Angiotensin II Acting on the Angiotensin II Type 2 Receptor , 2015, Circulation.

[168]  H. Mischak,et al.  Body fluid peptide and protein signatures in diabetic kidney diseases. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.